Improved human T-cell responses against synthetic HLA-0201 analog peptides derived from the WT1 oncoprotein (Q40228775)

18 September 2017

title

Improved human T-cell responses against synthetic HLA-0201 analog peptides derived from the WT1 oncoprotein (English)

1 reference

18 September 2017

Pinilla-Ibarz J

1

1 reference

18 September 2017

May RJ

2

1 reference

18 September 2017

Korontsvit T

3

1 reference

18 September 2017

Gomez M

4

1 reference

18 September 2017

Kappel B

5

1 reference

18 September 2017

Zakhaleva V

6

1 reference

18 September 2017

Zhang RH

7

1 reference

18 September 2017

Scheinberg DA

8

1 reference

18 September 2017

publication date

31 August 2006

1 reference

18 September 2017

1 reference

18 September 2017

volume

20

1 reference

18 September 2017

issue

11

1 reference

18 September 2017

page(s)

2025-2033

1 reference

Isolation and characterization of a zinc finger polypeptide gene at the human chromosome 11 Wilms' tumor locus

18 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404380

The candidate Wilms' tumour gene is involved in genitourinary development

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404380

Tissue, developmental, and tumor-specific expression of divergent transcripts in Wilms tumor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404380

The Wilms tumour gene WT1 is expressed in murine mesoderm-derived tissues and mutated in a human mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404380

Expression of the Wilms' tumor gene WT1 in the murine urogenital system

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404380

Significant correlation between the degree of WT1 expression and the International Prognostic Scoring System Score in patients with myelodysplastic syndromes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404380

Expression of the Wilms' tumor gene WT1 in solid tumors and its involvement in tumor cell growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404380

Constitutive expression of the Wilms' tumor gene (WT1) in the leukemic cell line U937 blocks parts of the differentiation program

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404380

Prediction of an HLA-DR-binding peptide derived from Wilms' tumour 1 protein and demonstration of in vitro immunogenicity of WT1(124-138)-pulsed dendritic cells generated according to an optimised protocol.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404380

Direct recognition and lysis of leukemia cells by WT1-specific CD4+ T lymphocytes in an HLA class II-restricted manner

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404380

Defining MHC class II T helper epitopes for WT1 tumor antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404380

Enhanced induction of human WT1-specific cytotoxic T lymphocytes with a 9-mer WT1 peptide modified at HLA-A*2402-binding residues.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404380

In vitro stimulation with WT1 peptide-loaded Epstein-Barr virus-positive B cells elicits high frequencies of WT1 peptide-specific T cells with in vitro and in vivo tumoricidal activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404380

WT1 peptide vaccination combined with BCG-CWS is more efficient for tumor eradication than WT1 peptide vaccination alone

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404380

Human cytotoxic T lymphocytes specific for Wilms' tumor antigen-1 inhibit engraftment of leukemia-initiating stem cells in non-obese diabetic-severe combined immunodeficient recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404380

Peptide binding motif predictive algorithms correspond with experimental binding of leukemia vaccine candidate peptides to HLA-A*0201 molecules

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404380

The use of computer-assisted video image analysis for the quantification of CD8+ T lymphocytes producing tumor necrosis factor alpha spots in response to peptide antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404380

Prominent role of secondary anchor residues in peptide binding to HLA-A2.1 molecules

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404380

Wilms' tumor gene WT1: its oncogenic function and clinical application

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404380

Constitutive expression of the Wilms' tumor gene WT1 inhibits the differentiation of myeloid progenitor cells but promotes their proliferation in response to granulocyte-colony stimulating factor (G-CSF).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404380

CD8 T-cell responses to Wilms tumor gene product WT1 and proteinase 3 in patients with acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404380

Functional leukemia-associated antigen-specific memory CD8+ T cells exist in healthy individuals and in patients with chronic myelogenous leukemia before and after stem cell transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404380

T-cell responses directed against multiple HLA-A*0201-restricted epitopes derived from Wilms' tumor 1 protein in patients with leukemia and healthy donors: identification, quantification, and characterization

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404380

Ex vivo characterization of multiepitopic tumor-specific CD8 T cells in patients with chronic myeloid leukemia: implications for vaccine development and adoptive cellular immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404380

Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404380

Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404380

Optimal activation of tumor-reactive T cells by selected antigenic peptide analogues.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404380

Elimination of human leukemia cells in NOD/SCID mice by WT1-TCR gene-transduced human T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404380

Synthetic peptides derived from the Wilms' tumor 1 protein sensitize human T lymphocytes to recognize chronic myelogenous leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404380

Two distinct HLA-A0201-presented epitopes of the Wilms tumor antigen 1 can function as targets for leukemia-reactive CTL

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404380

Complete remission in a patient with recurrent acute myeloid leukemia induced by vaccination with WT1 peptide in the absence of hematological or renal toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404380

The Wilms' tumor gene is frequently expressed in acute myeloblastic leukemias and may provide a marker for residual blast cells detectable by PCR

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404380

7 January 2021

Humoral immune responses against Wilms tumor gene WT1 product in patients with hematopoietic malignancies

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404380

7 January 2021

Human cytotoxic T-lymphocyte responses specific for peptides of the wild-type Wilms' tumor gene (WT1 ) product

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404380

7 January 2021

Cytotoxic T-lymphocyte responses elicited to Wilms' tumor gene WT1 product by DNA vaccination

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404380

7 January 2021

Quantitative assessment of WT1 expression by real time quantitative PCR may be a useful tool for monitoring minimal residual disease in acute leukemia patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404380

7 January 2021

A general strategy to enhance immunogenicity of low-affinity HLA-A2. 1-associated peptides: implication in the identification of cryptic tumor epitopes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404380

7 January 2021

Identifiers

DOI

10.1038/SJ.LEU.2404380

1 reference

Dimensions Publication ID

18 September 2017

1007730618

0 references

1 reference